Testogel is a transdermal testosterone replacement therapy licensed in the UK for treating male hypogonadism, a condition characterised by clinically low testosterone levels. Many men with confirmed testosterone deficiency experience reduced libido (sex drive), and restoring physiological testosterone levels through Testogel can improve sexual desire and function. However, it is crucial to understand that Testogel only improves libido when low sex drive is caused by biochemically confirmed testosterone deficiency. This article examines how Testogel affects libido, the expected timeframe for improvement, who should avoid this treatment, and alternative approaches for managing low sexual desire in accordance with UK clinical guidance.

What Is Testogel and How Does It Work?

Testogel is a transdermal testosterone replacement therapy (TRT) licensed in the UK for treating male hypogonadism—a condition characterised by abnormally low testosterone levels. It is available in two formulations: a 1% gel in 50 mg/5 g sachets and a 16.2 mg/g gel in a pump dispenser (delivering approximately 20.25 mg per actuation), applied daily to clean, dry skin.

The active ingredient, testosterone, is absorbed through the skin into the bloodstream, where it supplements the body's natural hormone production. Testosterone plays a crucial role in male sexual function, including libido (sex drive), erectile function, and overall sexual satisfaction. In men with confirmed testosterone deficiency, restoring physiological testosterone levels can improve sexual desire and performance.

Mechanism of action: Once absorbed, testosterone binds to androgen receptors in various tissues, including the brain, where it influences neurotransmitter systems involved in sexual arousal and motivation. It also supports nitric oxide production in penile tissue, which is essential for achieving and maintaining erections. However, it is important to emphasise that Testogel is only effective for libido problems caused by clinically low testosterone. The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Testogel specifically for hypogonadism, not for general sexual enhancement or age-related decline in otherwise healthy men.

Application instructions: The 50 mg/5 g sachets can be applied to the shoulders, upper arms, or abdomen, while the 16.2 mg/g pump formulation should only be applied to the shoulders or upper arms. The gel should be applied to clean, dry, intact skin, avoiding the genital area. Allow the gel to dry completely before dressing, and wash hands thoroughly with soap and water after application. Cover the application site with clothing once dry, and avoid showering or swimming for at least 2 hours after application.

Before prescribing Testogel, clinicians must confirm testosterone deficiency through two separate early morning blood tests showing low serum testosterone (using laboratory-specific reference ranges), alongside symptoms such as reduced libido, fatigue, or erectile dysfunction. Free testosterone measurement may be considered if sex hormone binding globulin (SHBG) levels are abnormal. Testosterone therapy should not be initiated without biochemical confirmation of deficiency in symptomatic men.

How Long Does Testogel Take to Affect Sex Drive?

The timeframe for Testogel to improve libido varies between individuals and depends on several factors, including baseline testosterone levels, overall health, and adherence to treatment. Most men begin to notice improvements in sexual desire within 3 to 6 weeks of starting therapy, though optimal benefits may take 3 to 6 months to fully manifest.

Early changes (2–4 weeks): Testosterone levels typically stabilise within the first few weeks of daily application. Some men report subtle improvements in mood, energy, and motivation during this period, which can indirectly influence sexual interest. However, significant changes in libido usually require sustained physiological testosterone levels.

Intermediate effects (6–12 weeks): Clinical studies suggest that improvements in sexual function, including libido and erectile quality, become more pronounced after 6 to 12 weeks of consistent use. This aligns with the time needed for testosterone to exert its effects on central nervous system pathways regulating sexual desire and peripheral mechanisms supporting erectile function.

Long-term optimisation (3–6 months): Maximum therapeutic benefit is generally achieved after 3 to 6 months. Testosterone levels should be monitored through blood tests after initiation or dose changes (typically at 2-3 months), then periodically thereafter. The dose should be adjusted to maintain testosterone within the mid-normal range of laboratory-specific reference values.

Safety monitoring: Regular monitoring should include haematocrit (at baseline, 3-6 months, 12 months, then annually), PSA and digital rectal examination according to age and risk factors, and blood pressure checks. Symptom review should be conducted at follow-up appointments.

Important considerations: If libido does not improve after 6 months of adequate testosterone replacement, other contributing factors should be investigated. These may include psychological issues (depression, anxiety, relationship difficulties), comorbid conditions (diabetes, cardiovascular disease), medications (antidepressants, antihypertensives), or lifestyle factors (obesity, excessive alcohol consumption, poor sleep). A holistic assessment of sexual dysfunction is recommended rather than relying solely on hormonal intervention. Patients should maintain regular follow-up appointments to monitor treatment efficacy and safety.

Who Should Not Use Testogel for Low Libido?

Testogel is contraindicated in several patient groups, and its use requires careful consideration of potential risks. Understanding these contraindications is essential for patient safety and appropriate prescribing.

Absolute contraindications include:

• Prostate or breast cancer: Testosterone can stimulate the growth of hormone-sensitive tumours. Men with known or suspected prostate or breast cancer must not use Testogel. Before initiating therapy, clinicians should perform a digital rectal examination and measure prostate-specific antigen (PSA) levels, with frequency of monitoring based on age and risk factors.

• Hypersensitivity to testosterone or any excipients in the formulation.

• Women and children: Testogel is not indicated for use in women or children and can cause virilisation if accidentally transferred.

Cautions and relative contraindications:

• Severe cardiac, renal, or hepatic impairment: Testosterone therapy may cause fluid retention and oedema. Patients with these conditions require careful monitoring.

• Cardiovascular risk: The MHRA advises that testosterone should only be used in men with confirmed hypogonadism. While evidence regarding cardiovascular risk is not conclusive, patients with pre-existing cardiovascular disease should be monitored closely.

• Polycythaemia: Testosterone stimulates red blood cell production. Men with elevated haematocrit should be monitored carefully, and treatment may need to be adjusted or discontinued if haematocrit exceeds 54%.

• Obstructive sleep apnoea: Testosterone may worsen this condition, which itself contributes to cardiovascular risk and fatigue. Consider appropriate monitoring and management.

• Normal testosterone levels: Men with libido problems but normal testosterone levels should not receive Testogel. Low libido in these cases is unlikely to be testosterone-responsive and may reflect psychological, relationship, or other medical issues.

• Fertility concerns: Testosterone therapy suppresses spermatogenesis and can cause infertility. Men wishing to father children should explore alternative treatments.

Transfer risk: Testogel can transfer to others through skin-to-skin contact, potentially causing virilisation in women and children. Application sites must be covered with clothing, and hands washed thoroughly with soap and water after use. Sexual partners and children should avoid contact with application areas until the gel has dried completely. If accidental exposure occurs, the affected area should be washed immediately with soap and water.

Any suspected adverse reactions to Testogel should be reported via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk).

Alternatives to Testogel for Improving Libido

When Testogel is unsuitable or ineffective, several alternative approaches can address low libido, depending on the underlying cause. A comprehensive assessment is essential to identify contributing factors and tailor treatment accordingly.

Other testosterone formulations:

For men with confirmed hypogonadism who cannot use Testogel (e.g., due to skin reactions or transfer concerns), alternative testosterone preparations available in the UK include:

• Tostran 2% (20 mg/g) gel: Applied to the abdomen or thighs.

• Testim 50 mg gel: Applied to the shoulders and upper arms.

• Intramuscular injections: Testosterone undecanoate (Nebido) administered every 10–14 weeks or testosterone mixtures (Sustanon) given every 2–3 weeks, avoiding daily application and transfer risks.

Testosterone patches and oral preparations have limited availability in the UK and are rarely used in routine practice.

Phosphodiesterase-5 (PDE5) inhibitors:

For men with erectile dysfunction contributing to reduced sexual activity and interest, medications such as sildenafil, tadalafil, or vardenafil can improve erectile function. These are particularly effective when erectile problems are vascular in origin and can be prescribed alongside testosterone therapy if appropriate. NICE recommends considering PDE5 inhibitors as first-line treatment for erectile dysfunction, regardless of testosterone status.

Important safety note: PDE5 inhibitors are contraindicated in patients taking nitrates and should be used with caution in those on alpha-blockers due to the risk of significant hypotension. Cardiovascular risk assessment is recommended before prescribing.

Fertility-preserving options:

For men with hypogonadism who wish to preserve fertility, specialist referral may be appropriate to consider treatments such as human chorionic gonadotropin (hCG) or selective oestrogen receptor modulators (SERMs) in specific circumstances.

Psychological and relationship interventions:

Low libido frequently has psychological components, including:

• Depression and anxiety: Antidepressant therapy or cognitive behavioural therapy (CBT) may be beneficial, though some antidepressants can themselves reduce libido.

• Relationship difficulties: Psychosexual counselling or couples therapy can address interpersonal factors affecting sexual desire.

• Performance anxiety: Sex therapy techniques can help men overcome anxiety-related sexual dysfunction.

Lifestyle modifications:

Evidence supports several lifestyle interventions for improving sexual function:

• Weight loss: Obesity is associated with lower testosterone levels and reduced libido. Achieving a healthy BMI can naturally increase testosterone production.

• Exercise: Regular physical activity, particularly resistance training, supports hormonal health and cardiovascular function.

• Sleep optimisation: Addressing sleep disorders and ensuring adequate sleep duration improves testosterone production.

• Alcohol reduction: Excessive alcohol consumption suppresses testosterone and impairs sexual function.

• Smoking cessation: Smoking damages vascular health, contributing to erectile dysfunction.

When to seek medical advice:

Patients experiencing persistent low libido should consult their GP for comprehensive evaluation, including blood tests, medication review, and assessment of psychological and relationship factors. Urgent referral is warranted for symptoms suggesting pituitary disease (severe headaches, visual field defects, galactorrhoea). Referral to endocrinology or sexual health services may be appropriate for complex cases.

Frequently Asked Questions